Strike Pharma

Executive Summary

Strike Pharma is a Swedish biotech company founded in 2018 that is developing a proprietary platform for the targeted delivery of lipid nanoparticles (LNPs) to enable in vivo CAR T-cell therapies. The company's technology aims to overcome the limitations of current ex vivo CAR T-cell manufacturing by directly reprogramming immune cells inside the body, potentially reducing costs and broadening access to these therapies. Initially focused on autoimmune diseases and cancer, Strike Pharma's approach could offer a transformative alternative to traditional cell therapies by eliminating the need for complex and expensive personalized manufacturing processes. The platform leverages targeted LNPs to deliver genetic payloads to specific immune cell populations, enabling in vivo generation of CAR T-cells. While the company is still in the preclinical stage and has not disclosed total funding, its innovative approach addresses a key bottleneck in cell therapy, positioning it as a potential disruptor in the field. However, significant technical and regulatory hurdles remain, and the company will need to demonstrate robust preclinical proof-of-concept and secure further investment to advance toward clinical trials.

Upcoming Catalysts (preview)

• Q4 2026Presentation of in vivo proof-of-concept data in autoimmune disease model60% success
• Q2 2027Series A financing round closure50% success
• Q1 2027IND-enabling studies completion for lead candidate40% success